Moleculin reaches 45-patient milestone in pivotal leukemia trial
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/14/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Super Micro Computer establishes $1.25 billion stock sale agreement
- Wall Street ends higher as SpaceX's market debut dominates
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- SpaceX Shares Indicated To Open At $155
Moleculin Hits 45 Subject Enrollment Milestone, Triggering Final Countdown to Mid-2026 MIRACLE Trial Data Readout
March 23, 2026 8:32 AM EDTFirst Interim Unblinding of Pivotal AML Trial Now Imminent Potentially the Most Important Data Moment in Company History
Early Blinded Results Show 40% Remission Rate Across Difficult-to-Treat Patient Population
Enrollment Accelerating Toward 90 Subject Threshold as Phase 3 Pathway Takes Shape
HOUSTON, March 23, 2026 (GLOBE NEWSWIRE) -- Moleculin Biotech, Inc., (Nasdaq: MBRX) (Moleculin or the Company), today... More
